Clinical trial · Observational

Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer

Effect of Genetic Polymorphisms on Clinical Outcome of Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients

NCT03154242CI-TRIAL-00027593unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Carcinoma, Non-Small-Cell Lung	Lung Non-Small Cell Carcinoma	ALIAS	0.90

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Progression-free survival (PFS)
timeFrame
From the date of starting the chemotherapy until the date of documented disease progression or date of death from any cause assessed up to 12 months
description
It's defined as the time from day 1 of chemotherapy to the day of documented disease progression or death from any cause.

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

1. Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC).
2. Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-2.
3. Chemotherapy naïve.
4. Age \>18 years.
5. Adequate bone marrow reserve

Exclusion Criteria:

1. Presence of Central nervous system(CNS) metastases.
2. Inadequate liver function
3. Inadequate renal function
4. Serious comorbid systemic disorder incompatible with the study.
5. Pregnancy

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Mar 20, 2017
Primary completion: Dec 1, 2018
Completion: Dec 1, 2018
First posted: May 16, 2017
Last update posted: May 16, 2017
Enrollment: 60 (estimated)
Lead sponsor: Ain Shams University OTHER
Keywords: non small cell lung cancer, NSCLC, Platinum

Data updated 22 days agoSource updated May 16, 2017source: clinicaltrials

Locations

Locations by country (1)

Country	Sites	Recruiting
Egypt	1	1

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.